AEGIR.ST
AegirBio AB (publ) [AEGIR.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AEGIR.ST Stock Summary
In the News
AEGIR.ST Financial details
Company Rating
-
Market Cap
20.75M
Income
-368.57M
Revenue
99K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
14
Optionable
No
Shortable
Yes
Earnings
27 Aug 2020
P/E
-0.05
Forward P/E
-
PEG
-0
P/S
311.89
P/B
2.52
P/C
-
P/FCF
-0.62
Quick Ratio
2.12
Current Ratio
2.53
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-17.06
EPS next Y
-
EPS next Q
-
EPS this Y
235.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
3500%
EPS Q/Q
2.99%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-569%
ROE
-904%
ROC
-6.83%
Gross Margin
-24399%
Oper. Margin
-370291%
Profit Margin
-372297%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.5-2.198
52W High
-
52W Low
-
RSI
-
Rel Volume
1.44
Avg Volume
117.77K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
2.573
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 117.77K
- Market Capitalization 20.75M
- Employee 14
- CEO Mr. Marco Wititteveen
- Headquarters Lund,SE
- IPO Date 2020-06-26
-
Website
https://aegirbio.com 
AegirBio AB (publ), a diagnostic company, develops and commercializes tests to follow the dosage of biological drugs. The company focuses on therapeutic drug monitoring of biologic therapies in the multiple sclerosis, cancer, and autoimmune diseases. It offers moNATor, a first dose-monitoring laboratory test to test multiple sclerosis for healthcare professionals and patients; and Viraspec, a COVID-19 saliva test kit. The company was incorporated in 2019 and is based in Lund, Sweden.
